News

Titan and Molteni, a European-based pharmaceutical company focused on treatments for pain and drug addiction, expect to enter into the definitive license and distribution agreement during the first

The randomized, placebo-controlled, double-blind phase 1 trial will feature 240 male and female subjects aged between 18 and 49. It will assess the safety and immunogenicity of the investigational

Genentech will conduct the multicenter trial, which will enroll approximately 40 patients in the initial phase of the study. “We are pleased to be working with one of

Eylea injection is a vascular endothelial growth factor (VEGF) inhibitor formulated as an injection for the eye. It is designed to inhibit the growth of new blood vessels

The ATLAS-2M study is designed to demonstrate the non-inferior antiviral activity, at 48 weeks of treatment, of long-acting cabotegravir and long-acting rilpivirine administered every eight weeks compared with

“This partnership is further evidence of Biogen’s ongoing commitment to multiple sclerosis and builds upon our deep experience in neuroscience and particularly in MS,” stated Michel Vounatsos, Chief Executive Officer

The new research hub will focus its research on early bioscience discovery and entrepreneurial innovation. According to MSD, by locating a research hub in London, it will be

Tagrisso is a third-generation and irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with clinical activity against central nervous system (CNS) metastases. It is designed to

The submission includes data from two completed trials of RUCONEST® for the prophylaxis of HAE attacks: a randomized, double-blind, placebo-controlled trial and an open-label study. The two studies